ELTE-led consortium winds up drug development project
Image by posztos/Shutterstock.com
A consortium led by Budapest's Eötvös Loránd University (ELTE) has completed a HUF 1.8 billion project to develop a drug to treat patients suffering from spastic limbs after stroke, ELTE told news agency MTI.
The compound the consortium developed, MPH-220, promotes neurite growth to reduce muscle spasms common after nervous system injuries such as stroke. The compound has made it through the pre-clinical phase of tests, clearing the way for phase I clinical tests.
Talks with groups of investors have started on cooperating on the possible clinical development of the compound.
ELTE was joined in the consortium by Printnet and Neuroct. András Málnási-Csizmadia led the project, dubbed Neurelaxin, which was supported by a HUF 1.5 bln grant from the National Competitiveness and Excellence Program.
Rail Cargo Group Leases Logisztár Terminal to S. Korean Logi...
Liz & Chain Rooftop Bar Debuts Sustainable Cocktails
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
